kabutan

Medrx shares plunge after schizophrenia drug trial fails to meet primary endpoint

Thu Apr 2, 2026 10:04 am JST Catalyst

Medrx Co.,Ltd. <4586> shares fell sharply. The company announced earlier in the day topline results from a Phase 2 clinical trial of Alto-101, a schizophrenia treatment drug (PDE4 inhibitor patch) being developed in partnership with U.S. biopharmaceutical venture Alto Neuroscience , in patients with schizophrenia. The trial did not achieve statistically significant results for its primary endpoint. The company stated it will determine future direction after discussions with Alto. The news is being viewed negatively by the market.

Source: MINKABU PRESS

Related Articles